Abstract

BILIRUBIN NANOMEDICINES FOR THE TREATMENT OF REACTIVE OXYGEN SPECIES (ROS)-MEDIATED DISEASES

Mr. Arpit Rajaram Suralkar*, Mr. Kiran Vishnu Sanap, Ms. Komal Suresh Age, Ms. Sumedha Prabhudas Tayade, Ms. Ankita Jayprakash Parit

ABSTRACT

Reactive oxygen species (ROS) play a crucial role in the pathogenesis of numerous diseases, including neurodegenerative disorders, cardiovascular diseases, and various cancers. Their overproduction leads to oxidative stress, causing cellular damage and contributing to disease progression. Bilirubin, a natural byproduct of heme metabolism, exhibits potent antioxidant properties, making it a promising candidate for therapeutic applications. This review explores the development and potential of bilirubin nanomedicines, which enhance the stability, bioavailability, and targeted delivery of bilirubin. Various nanocarrier systems, including nano-emulsions, nanoparticles, liposomes, and nanosuspensions, are discussed for their effectiveness in improving therapeutic outcomes. The review highlights the applications of bilirubin nanomedicines in treating ROS-mediated diseases, showcasing their neuroprotective, cardioprotective, anti-cancer, and anti-inflammatory effects. Despite the promising potential, challenges such as formulation stability, regulatory hurdles, and the need for comprehensive efficacy studies remain. Future research should focus on optimizing these nanomedicine formulations and exploring combination therapies to maximize their therapeutic benefits. Overall, bilirubin nanomedicines offer a novel approach to mitigate oxidative stress and improve treatment outcomes in ROS-mediated diseases.

Keywords: Bilirubin, Nanomedicine, Reactive Oxygen Species (ROS), Oxidative Stress, Antioxidant Properties, Neurodegenerative Disorders, Cardiovascular Diseases, Cancer Therapy.